This week, a 40-year-old patient was treated at UNC’s Clinical and Translational Research Center (CTRC) with SB-913, an investigational genome editing therapy for individuals with mucopolysaccharidosis type II (MPS II), a rare lysosomal storage disorder also known as Hunter syndrome. Read more >>